[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diverticulitis-of-sigmoid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diverticulitis-of-sigmoid":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100362114","bowel-functionqol-after-elective-sigmoidectomy-vs-conservative-management-for-recurrent-uncomplicated-diverticulitis-100362114",false,"NCT03994978","Bowel Function\u002FQoL After Elective Sigmoidectomy vs. Conservative Management for Recurrent Uncomplicated Diverticulitis","Preoperative vs. Postoperative Bowel Function and Quality of Life in Patients Undergoing Elective Sigmoidectomy vs. Conservative Management for Recurrent Uncomplicated Diverticulitis (FRESCO-Trial)","Inclusion Criteria:\n\n* Patients with recurrent uncomplicated diverticulitis and surgical indication for sigmoid resection\n* Patients with recurrent uncomplicated diverticulitis and non-surgical indication for conservative management\n* Confirmation of at least one episode of acute uncomplicated diverticulitis in computed tomography\n\nExclusion Criteria:\n\n* Patients aged under 18.\n* Patients unable to understand an informed consent.\n* Patients with chronic pain disorder.\n* Patients with sigmoid fistulas\n* Emergency operations.\n* Pregnant women or lactation.\n* Patients with other severe gastrointestinal diseases, such as inflammatory bowel diseases (IBD), carcinoma or immunologic disorders.\n* Patients unable to perform surgery or high-risk patients according to the American Society of Anesthesiology (ASA 4 grade or higher)","ALL","18 Years",{"count":19,"type":20},252,"ESTIMATED","OBSERVATIONAL","The decision to perform a surgical intervention or not after recovery from repeated uncomplicated episodes of acute diverticulitis remains controversial and the literature shows different conflicting approaches based on low-quality evidence.The goal of this trial is to achieve a better understanding of the impact of surgery on bowel function and QoL in patients with recurrent uncomplicated sigmoid diverticulitis in order to develop treatment guidelines.",[24],"Diverticulitis of Sigmoid","RECRUITING","2026-05-18",{"date":28,"type":29},"2026-05-22","ACTUAL",{"date":31,"type":29},"2019-07-08",{"date":33,"type":20},"2028-12-31",{"name":35,"class":36},"University Hospital, Basel, Switzerland","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100511699","quality-of-life-in-acute-complicated-and-chronic-recurrent-left-sided-diverticulitis-100511699","NCT05942833","Quality of Life in Acute Complicated and Chronic Recurrent Left-sided Diverticulitis","DATE Trial: Outcomes and Quality of Life in Patients With Early Versus Elective Resection in Acute Complicated and Chronic Recurrent Left-sided Diverticulitis","DATE","Inclusion Criteria:\n\n* Informed consent to participate in the study\n* CDD Type 2a, 2b: acute complicated left-sided diverticulitis\n* CDD Type 3b: relapsing diverticulitis without complications (\\>2 episodes within 2 years)\n* Acute presentation\n* Inflammation located in the left-sided colon\n* Inflammation is CT proven or ultrasound confirmed from experienced radiologists\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* Pregnancy\n* BMI \\> 55kg\u002Fm2\n* Current colorectal carcinoma in the left-sided colon\n* Oral and\u002For intravenous corticosteroid\n* Ongoing chemotherapy\n* Status post left hemicolectomy\n* Patients who cannot take care of themselves at home or are unable to follow instructions\n* Patients who are not fit for surgery (anesthesia, expert knowledge from specialists) and will not benefit from surgery",{"count":47,"type":20},136,"INTERVENTIONAL",[50],"NA","Patients presenting in hospital with symptoms of acute diverticulitis. Acute inflammation of the left-sided colon is confirmed with CT scan or ultrasound in experienced centers and diagnosis is defined according to the \"Classification of Diverticular Disease (CDD)\". CDD Type 2a, 2b and 3b will be included and then randomized in two groups. Group A will get an early left hemicolectomy 7 to 10 days after admission and initial antibiotic therapy and\u002For drainage of the abscess. Group B is designated for an elective resection 6 to 8 weeks after dismissal at the earliest and initial conservative treatment and\u002For after drainage of the abscess. Six weeks after the operation patients of Group A will be asked for their present quality of life with a standardized scoring system (Gastrointestinal Quality of Life Index = GIQLI; Short-form 36 Score = SF-36 Score; Low anterior resection syndrome = LARS Score). Group B (elective resection) will be asked at their readmission prior to elective surgery is done. This survey package will be repeated again 6 to 8 weeks later in both groups. Primary endpoints will be the two GIQLI at the said examination times. Secondary endpoints will be SF-36 score, LARS-score, GIQLI-Domains, anastomosis insufficiency and other complications, mortality and length of hospital stay. Comparisons between the groups are made at the said examination times but also 6-8 weeks after the operation.",[24],[54,55,56,57,58],"Recurrent diverticulitis","Quality of life","Acute complicated Diverticulitis","Early resection","Elective resection","2026-03-16",{"date":61,"type":29},"2026-03-18",{"date":63,"type":29},"2023-01-16",{"date":65,"type":20},"2027-07",{"name":67,"class":36},"Kepler University Hospital",4,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":48,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":37},"100568911","phase-2-clinical-trial-with-mbk-01-intestinal-microbiota-capsules-for-the-treatment-of-patients-with-recurrent-diverticulitis-100568911","NCT06687382","Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis","A Phase IIa Randomized, Controlled, Open-label Clinical Trial to Assess the Efficacy, Safety, and Tolerability of the Investigational Medicinal Product MBK-01, FSPIM (Full Spectrum & Purified Intestinal Microbiota) Oral Capsules, as Well as to Determine the Optimal Dosage in the Treatment of Patients With Recurrent Diverticulitis (DIREBIOT)","Inclusion Criteria:\n\n* Patients of both sexes aged 18-70 (both included).\n* Three or more episodes compatible with a diagnosis of acute diverticulitis of the left or sigmoid colon in the 3 years prior to signing the informed consent. The diagnosis of each episode of diverticulitis must have been made by demonstrating inflammation in the colon compatible with diverticulitis in an imaging test (computed tomography or ultrasound) and presenting at least one of the following analytical or clinical alterations :abdominal pain, vomiting, intestinal obstruction, body temperature over 38ºC, constipation (less than one bowel movement every 3 days), elevated acute-phase reactants (leukocytes higher than 11,000 cells\u002FµL and\u002For C-reactive protein (CRP) higher than 5mg\u002FdL and\u002For procalcitonin higher than 0.2), rectal bleeding.\n* Not having had any symptomatic episode of acute diverticulitis in the 30 days prior to signing the informed consent.\n* In the case of women and men of reproductive age, for safety, those who agree to follow the required contraceptive measure from the signing of the informed consent until the penultimate visit of the follow-up period.\n* Patients who have signed the informed consent, either autonomously or through a legal representative.\n\nExclusion Criteria:\n\n* Patients for who the information on episodes of acute diverticulitis required for inclusion in the study cannot be fully verified.\n* Patients with acute diverticulitis in the ascending colon, transverse colon or other locations other than the descending or sigmoid colon.\n* Previous colonic resection of any segment of the colon.\n* Medical history of colorectal cancer.\n* Having taken a mechanical colonic preparation in the 3 months prior to signing the informed consent.\n* History of abdominal surgery.\n* Allergy or intolerance to any component of the investigational medicinal product or ancillary medicinal products (amoxicillin, clavulanic acid, fosfomycin or metronidazole) used in the trial.\n* Prior administration of fecal microbiota transplantation (FMT).\n* Systemic antibiotic treatment in the 30 days prior to signing the informed consent.\n* Taking a marketed probiotic\u002Fprebiotic\u002Fsymbiotic in the 30 days prior to signing the informed consent.\n* Treatment with rifaximin or mesalazine in the 30 days prior to signing the informed consent.\n* Presence of hereditary or acquired immunodeficiency.\n* Chronic infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).\n* Pregnancy or lactation.\n* Any other condition that, in the opinion of the investigator, could prevent or hinder compliance with the study.","70 Years",{"count":78,"type":20},81,[80],"PHASE2","Patients with diverticulitis experience a prolonged course of the disease and report a variety of physical, psychological and social symptoms, which highly impacts in their quality of life. Although antibiotic therapy has been the preferred treatment option for acute diverticulitis, it does not control the disease in 40 percent of the patients with complicated diverticulitis and 13 to 23 percent of the patients with non-complicated diverticulitis, which results in chronic and recurrent episodes of diverticulitis. As the episodes repeat, the outpatient conservative treatment has worse success rates and the incidence of complicated diverticulitis with abscess increases up to five times.\n\nTherefore, it is of great importance to establish new treatments in order to avoid the recurrences of the disease. As of today, there is not enough evidence of the efficacy of current treatment options to prevent recurrences in patients with diverticulitis, but recent approaches suggest the modification of intestinal microbiota as a preventive strategy.\n\nMicrobial imbalance (dysbiosis) has been proposed as a mechanism involved in the transition from diverticulosis to diverticulitis, inflammation and some of the symptoms of the disease. In this way, fecal microbiota transplantation (FMT) could have an important role in the prevention of new episodes, as it can modify the composition of the intestinal microbiota in a less invasive and more physiological way. Until now the efficacy of FMT in patients with recurrent diverticulitis has not been assessed; however, its benefits and safety have been demonstrated in studies for inflammatory bowel disease (IBD), a pathology with similarities to diverticulitis in its symptoms and underlying inflammation.\n\nThe objective of the present clinical trial is to assess the efficacy of MBK-01 (heterologous lyophilized intestinal microbiota oral capsules) in reducing the frequency of episodes in recurrent diverticulitis, its safety and tolerability and to determine the optimal dosing regimen.",[83,24],"Diverticulitis",[85,86,87,88,89,90,91],"Recurrent Diverticulitis","Diverticular Disease","Acute Diverticulitis","Diverticulosis","Fecal Microbiota Transplantation","Fecal Microbiota Transfer","Intestinal Microbiota","2025-06-04",{"date":94,"type":29},"2025-06-05",{"date":96,"type":29},"2025-04-03",{"date":98,"type":20},"2027-04",{"name":100,"class":101},"Mikrobiomik Healthcare Company S.L.","INDUSTRY"]